Celadon Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Celadon Pharmaceuticals's earnings have been declining at an average annual rate of -46.4%, while the Pharmaceuticals industry saw earnings declining at 0.9% annually. Revenues have been growing at an average rate of 109.9% per year.
Key information
-46.4%
Earnings growth rate
121.9%
EPS growth rate
| Pharmaceuticals Industry Growth | 14.1% |
| Revenue growth rate | 109.9% |
| Return on equity | -228.3% |
| Net Margin | -9,520.0% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Celadon Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -7 | 6 | 0 |
| 30 Sep 23 | 0 | -8 | 6 | 0 |
| 30 Jun 23 | 0 | -8 | 7 | 0 |
| 31 Mar 23 | 0 | -12 | 10 | 0 |
| 31 Dec 22 | 0 | -17 | 12 | 0 |
| 30 Sep 22 | 0 | -16 | 11 | 0 |
| 30 Jun 22 | 0 | -16 | 10 | 0 |
| 31 Mar 22 | 0 | -10 | 6 | 0 |
| 31 Dec 21 | 0 | -5 | 2 | 0 |
| 30 Sep 21 | 0 | -4 | 2 | 0 |
| 30 Jun 21 | 0 | -3 | 1 | 0 |
| 31 Mar 21 | 0 | -2 | 1 | 0 |
| 31 Dec 20 | 0 | -1 | 1 | 0 |
| 31 Aug 20 | 0 | 0 | 0 | 0 |
Quality Earnings: CEL is currently unprofitable.
Growing Profit Margin: CEL is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CEL is unprofitable, and losses have increased over the past 5 years at a rate of 46.4% per year.
Accelerating Growth: Unable to compare CEL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CEL is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (1.5%).
Return on Equity
High ROE: CEL has a negative Return on Equity (-228.29%), as it is currently unprofitable.